Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.77 |
| ▸ | CA1 | P00915 | 4/20 | 0.77 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28528409 | 0.98 | CA2 (0.74) | CA2CA1ZDHHC7MAPK1HDAC7 | |
| SCHEMBL8950290 | 0.96 | CA2 (0.83) | CA2CA1ZDHHC7MAPK1TDP1 | |
| SCHEMBL3679625 | 0.94 | CA2 (0.68) | CA2CA1ZDHHC7MAPK1HDAC7 | |
| SCHEMBL21052368 | 0.93 | CA2 (0.80) | CA2CA1ZDHHC7MAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL28119340 | 0.92 | CA2 (0.66) | CA2CA1ZDHHC7MAPK1HDAC7 | |
| SCHEMBL6353978 | 0.92 | CA2 (0.66) | CA2CA1ZDHHC7HDAC7HDAC8 | |
| SCHEMBL27812332 | 0.92 | CA2 (0.66) | CA2CA1ZDHHC7HDAC7HDAC8 | |
| SCHEMBL13808655 | 0.92 | CA2 (0.66) | CA2CA1ZDHHC7HDAC7HDAC8 | |
| SCHEMBL3681990 | 0.92 | CA2 (0.66) | CA2CA1ZDHHC7HDAC7HDAC8 | |
| SCHEMBL27449276 | 0.92 | CA2 (0.66) | CA2CA1ZDHHC7HDAC7HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221646-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117897382-A | Nitrogen-containing tricyclic compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2024-04-16 | — | — | CN | disclosed |
| CN-117800975-A | Compounds with anti-KRAS mutant tumor activity | 泰励生物科技（上海）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-112399874-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-115515936-A | Process for the preparation of (R) -4- (1- (6- (4- (trifluoromethyl) benzyl) -6-azaspiro [2.5] octane-5-carboxamido) -cyclopropyl) benzoic acid or a salt thereof | 罗达制药生物技术有限责任公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-109952360-B | Quantum dot dispersion, self-luminous photosensitive resin composition, color filter manufactured using the same, and image display device | 东友精细化工有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109810589-A | Light converts resin combination, light conversion layer folds substrate and image display device | 东友精细化工有限公司 | 2019-05-28 | — | — | CN | disclosed |
| EP-2794547-B1 | PROCESS FOR THE PREPARATION OF ESTERS FROM FORMATES AND COMPOUNDS OLEFINICALLY UNSATURATED | EVONIK DEGUSSA GMBH (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-20080045490-A1 | Pharmaceutical Compositions | BIOVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| US-6207739-B1 | Polyamide acid composition containing metal, polyimide film, flexible printed wiring board and method for producing them | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI (JP) | 2001-03-27 | — | — | US | disclosed |
| CN-1284942-A | matrix metalloproteinase inhibitors | PFIZER LTD (US) | 2001-02-21 | — | — | CN | disclosed |
| US-5463095-A | Process for the production of esters | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0629603-A1 | Process for the production of esters | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1994-12-21 | — | — | EP | disclosed |
| CN-1060285-A | The fused ring analogs of nitrogenous nonaromatic heterocycles | PFIZER (US) | 1992-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045490-A1 | Pharmaceutical Compositions | HSD3B1, HSD17B3, HSD17B1 | CA2 3762/4885CA1 3617/4885ZDHHC7 634/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | CA2 3601/4885CA1 3803/4885ZDHHC7 483/4885 |
| US-20070275936-A1 | Formulations and Treatment Methods | HSD3B1, HSD17B1, HSD17B3 | CA2 3848/4885CA1 3817/4885ZDHHC7 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.